Evidence map›Paper›PMID 42722673›Full record

ArticleNature communications2026

Perioperative myeloid cell remodeling shapes CAR-T cell efficacy in glioblastoma.

Martin Pedard, Luis Castillo Cantero, Ali Ghasemi, Eliana Marinari, Caterina Mollica, Suzel Davanture, Julie Pernot, Valérie Widmer, Doron Merkler, Kristof Egervari and 7 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Nature communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Martin PedardBrain Tumor and Immune Cell Engineering Laboratory, Center for Translational Research in Onco-Hematology, Faculty of Medicine, University of Geneva, Geneva, Switzerland. martin.pedard@unige.ch.ORCID http://orcid.org/0000-0003-1258-7825
Luis Castillo CanteroBrain Tumor and Immune Cell Engineering Laboratory, Center for Translational Research in Onco-Hematology, Faculty of Medicine, University of Geneva, Geneva, Switzerland.
Ali GhasemiBrain Tumor and Immune Cell Engineering Laboratory, Center for Translational Research in Onco-Hematology, Faculty of Medicine, University of Geneva, Geneva, Switzerland.
Eliana MarinariBrain Tumor and Immune Cell Engineering Laboratory, Center for Translational Research in Onco-Hematology, Faculty of Medicine, University of Geneva, Geneva, Switzerland.
Caterina MollicaDivision of Neurosurgery, Department of Clinical Neurosciences, Geneva University Hospitals, Geneva, Switzerland.
Suzel DavantureBrain Tumor and Immune Cell Engineering Laboratory, Center for Translational Research in Onco-Hematology, Faculty of Medicine, University of Geneva, Geneva, Switzerland.
Julie PernotBrain Tumor and Immune Cell Engineering Laboratory, Center for Translational Research in Onco-Hematology, Faculty of Medicine, University of Geneva, Geneva, Switzerland.
Valérie WidmerBrain Tumor and Immune Cell Engineering Laboratory, Center for Translational Research in Onco-Hematology, Faculty of Medicine, University of Geneva, Geneva, Switzerland.
Doron MerklerDivision of Clinical Pathology, Department of Diagnostics, Geneva University Hospitals Geneva, Geneva, Switzerland.ORCID http://orcid.org/0000-0002-0247-2007
Kristof EgervariDivision of Clinical Pathology, Department of Diagnostics, Geneva University Hospitals Geneva, Geneva, Switzerland.
Karl SchallerDivision of Neurosurgery, Department of Clinical Neurosciences, Geneva University Hospitals, Geneva, Switzerland.
Philippe BijlengaDivision of Neurosurgery, Department of Clinical Neurosciences, Geneva University Hospitals, Geneva, Switzerland.ORCID http://orcid.org/0000-0002-3586-2757
Andrea BartoliDivision of Neurosurgery, Department of Clinical Neurosciences, Geneva University Hospitals, Geneva, Switzerland.
Shahan MomjianDivision of Neurosurgery, Department of Clinical Neurosciences, Geneva University Hospitals, Geneva, Switzerland.
Mikael J PittetAgora Cancer Research Center, Lausanne, Switzerland.ORCID http://orcid.org/0000-0002-2060-4691
Valérie DutoitBrain Tumor and Immune Cell Engineering Laboratory, Center for Translational Research in Onco-Hematology, Faculty of Medicine, University of Geneva, Geneva, Switzerland.ORCID http://orcid.org/0000-0002-3469-4237
Denis MiglioriniBrain Tumor and Immune Cell Engineering Laboratory, Center for Translational Research in Onco-Hematology, Faculty of Medicine, University of Geneva, Geneva, Switzerland. denis.migliorini@unige.ch.ORCID http://orcid.org/0000-0003-0151-3222

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Glioblastoma (GBM) is characterized by a profoundly immunosuppressive tumor microenvironment (TME) that constrains the efficacy of chimeric antigen receptor (CAR)-T cell therapy. Here, we show that surgical resection in both male mice and human GBM ex vivo induces a rapid and sustained remodeling of the TME, marked by upregulation of TREM2 in myeloid cells followed by emergence of T cell exhaustion-like phenotypes. In male mice, targeting TREM2 reshapes the perioperative TME and potentiates tumor antigen-specific CAR-T cell responses, improving intratumoral persistence, proliferation, and effector differentiation, and resulting in enhanced survival. In parallel, we identify the timing of CAR-T cell administration as a critical determinant of therapeutic outcome, with neoadjuvant outperforming adjuvant treatment by preserving CAR-T cell effector function in mice. These findings establish perioperative myeloid cell remodeling and treatment timing as key determinants of CAR-T cell efficacy in GBM.

Indexed as

Brain NeoplasmsGlioblastomaImmunotherapy, AdoptiveMyeloid CellsReceptors, Chimeric AntigenAnimalsCell Line, TumorHumansMaleMembrane GlycoproteinsMiceReceptors, ImmunologicT-Cell ExhaustionT-LymphocytesTumor MicroenvironmentMembrane GlycoproteinsReceptors, Chimeric AntigenReceptors, Immunologic

Identifiers

PMID42722673
PMCPMC13562681

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.